Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France

Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3

(2017) Christophe Le Clorennec et al.   MOLECULAR CANCER THERAPEUTICS

Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

(2017) Nikolas Stefan et al.   MOLECULAR CANCER THERAPEUTICS

Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Cysteine Insertion

(2017) Nazzareno Dimasi et al.   MOLECULAR PHARMACEUTICS

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [ 18 F]FBEM and in vivo PET studies

(2017) Sylvestre Dammicco et al.   NUCLEAR MEDICINE AND BIOLOGY

From R&D to Clinical Supplies

(2017) Amar S. Prashad et al.   ORGANIC PROCESS RESEARCH & DEVELOPMENT

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity

(2016) M. L. Miller et al.   MOLECULAR CANCER THERAPEUTICS

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

(2016) Patrick J. Burke et al.   MOLECULAR CANCER THERAPEUTICS

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional characterization of p7 viroporin from hepatitis C virus produced in a cell-free expression system

(2016) Thomas Soranzo et al.   PROTEIN EXPRESSION AND PURIFICATION

Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

(2016) Arnaud C. Tiberghien et al.   ACS Medicinal Chemistry Letters

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

(2016) Stephen R. Adams et al.   Nature Communications

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

(2016) Christophe Le Clorennec et al.   Oncotarget

Emerging formats for next-generation antibody drug conjugates

(2015) Mahendra P Deonarain et al.   Expert Opinion on Drug Discovery

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

IMGN853, a Folate Receptor-  (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors

(2015) O. Ab et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

(2015) F. Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

TP53 loss creates therapeutic vulnerability in colorectal cancer

(2015) Yunhua Liu et al.   NATURE

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

(2015) Roger R. Beerli et al.   PLoS One

Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates

(2014) Patrick Dennler et al.   BIOCONJUGATE CHEMISTRY

Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

(2014) J Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

(2014) Antoine Deslandes   mAbs

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2

(2014) A Kroiss et al.   ONCOGENE

EndoS2is a unique and conserved enzyme of serotype M49 group AStreptococcusthat hydrolyses N-linked glycans on IgG and α1-acid glycoprotein

(2013) Jonathan Sjögren et al.   BIOCHEMICAL JOURNAL

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice

(2013) Mathieu Frindel et al.   NUCLEAR MEDICINE AND BIOLOGY

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

(2009) Hans K. Erickson et al.   BIOCONJUGATE CHEMISTRY